Clinical trials: Autoimmune Disorders
Relapsing Remitting Multiple Sclerosis
Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).
Teva is developing a 40 mg/ml GA Injection, administered once daily under the skin, for the treatment of R-R MS. The study drug is a higher dose formulation of Copaxone® (20 mg/ml GA), a marketed medication, approved for the…
- Trial name
- NCT00337779
- Testing
- Glatiramer Acetate (GA) 40 mg, glatiramer acetate 20 mg
- Volunteers
- 1,155 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Comparative Effectiveness Study Telerehab Versus Conventional
This study aims to compare the effectiveness of an exercise program delivered in a conventional facility-based format versus a telerehabilitation format, which takes place in the home.
- Trial name
- NCT03468868
- Testing
- Exercise program for people with MS
- Where
- 9 sites in United States
- Volunteers
- 379 people
- Sponsor
- Shepherd Center, Atlanta GA
Arthritis, Rheumatoid
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
- Trial name
- NCT01955733
- Testing
- BI 695500
- Where
- 43 sites in United States, Belgium and 7 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Myasthenia Gravis, Generalized
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
The primary objective is to evaluate whether IGIV-C improves MG symptoms as compared to placebo in subjects with MG.
- Trial name
- NCT02473952
- Testing
- IGIV-C
- Where
- 40 sites in United States, Belgium and 8 more
- Volunteers
- 62 people
- Sponsor
- Grifols Therapeutics LLC
Multiple Sclerosis (MS)
Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis
The purpose of this study is to determine if a sequential combination therapy of natalizumab and alemtuzumab induces peripheral tolerance and reduces the annualized relapse rate (ARR) in patients with relapsing-remitting multiple…
- Trial name
- SUPPRESS (NCT03135249)
- Testing
- Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of Texas Southwestern Medical Center
Inherited Mitochondrial Disease
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical…
- Trial name
- NCT05218655
- Testing
- Vatiquinone
- Where
- 26 sites in United States, France and 5 more
- Volunteers
- 101 people
- Sponsor
- PTC Therapeutics
Relapsing Remitting Multiple Sclerosis
Fingolimod Effect on Cytokine and Chemokine Levels
The main purpose of this study was to measure the serum levels of cytokines and chemokines that are known to increase during multiple sclerosis relapses.
- Trial name
- NCT02373098
- Testing
- Fingolimod 0.5 mg
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
PANS, PANDAS
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype
The purpose of this research study is to know if the antibiotic azithromycin, an antibiotic approved by the U.S. Food and Drug Administration (FDA) for treating infections, improves symptom severity in children with sudden and…
- Conditions
- PANS, PANDAS, Obsessive Compulsive Disorder (OCD)
- Trial name
- AZT (NCT01617083)
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of South Florida
Multiple Sclerosis
Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis
The purpose of this study is to investigate whether a wearable robotic exoskeleton can help people with multiple sclerosis (MS) to walk again.
- Trial name
- NCT02519244
- Testing
- Ekso® (Wearable lower limb exoskeleton)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The University of Texas Health Science Center, Houston
Type 1 Diabetes
Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients
The purpose of this study is to determine if DiaPep277 can effectively protect the internal production of insulin in patients newly diagnosed with type 1 diabetes, by stopping the immune destruction of insulin-producing…
- Trial name
- DIA-AID (NCT00615264)
- Testing
- DiaPep277
- Where
- 34 sites in Austria, Czechia and 9 more
- Volunteers
- 457 people
- Sponsor
- Andromeda Biotech Ltd.
Systemic Lupus Erythematosus
BENLYSTA® Special Drug Use Investigation
The objective of this study is to collect and assess the information about long-term safety and effectiveness of Benlysta for intravenous injection and Benlysta for subcutaneous injection (hereinafter referred to as "Benlysta")…
- Trial name
- NCT03370263
- Testing
- Benlysta
- Where
- Japan
- Volunteers
- 1,514 people
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and a major health problem. The purpose of this study is to determine the safety and effectiveness of lovastatin for controlling inflammation in mildly active RA.
- Trial name
- NCT00302952
- Testing
- Lovastatin
- Where
- 15 sites in United States
- Volunteers
- 64 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
This is a randomized, double-blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and PK of a higher dose of ocrelizumab per intravenous (IV) infusion every 24 weeks (Q24W) in participants with RMS…
- Trial name
- MUSETTE (NCT04544436)
- Testing
- Ocrelizumab, Antihistamine, Methylprednisolone
- Where
- 120 sites in United States, Argentina and 19 more
- Volunteers
- 864 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.
- Trial name
- PUMP (NCT00607087)
- Testing
- Insulin glulisine, Insulin lispro, Insulin aspart
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Solid Organ Transplant Recipients, Autoimmune Diseases
Mass Evaluation of Lateral Flow Immunoassays for the Detection of SARS-CoV-2 (Covid-19) Antibodies
DESIGN Observational epidemiological study AIMS - To determine: 1. The proportion of immunosuppressed people who have detectable SARS-CoV-2 antibodies following a primary vaccine course (3 doses), and the demographic, disease…
- Conditions
- Solid Organ Transplant Recipients, Autoimmune Diseases, Haematological Malignancies
- Trial name
- MELODY (NCT05148806)
- Testing
- self-administered lateral flow assays
- Where
- 4 sites in United Kingdom
- Volunteers
- 28,411 people
- Sponsor
- Imperial College London
Type 1 Diabetes Mellitus
Communication and Coping for Mothers of Adolescents With Type 1 Diabetes
Mothers of adolescents with type 1 diabetes experience high levels of depressive symptoms, which impair their ability to monitor and manage diabetes treatment effectively.
- Trial name
- T1D (NCT03818711)
- Testing
- Communication & Coping Intervention, Education & Check Ins
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- Vanderbilt University Medical Center
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)
This open-label, single arm study evaluated the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis.
- Trial name
- NCT02010216
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 6 sites in Kazakhstan
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Type 2 Diabetes
Nurse Telephone Management of Cholesterol in Diabetes
The current project is evaluating the effect of a nurse-administered phone care in diabetes to improve access to care and healthcare delivery.
- Trial name
- NATCHOS (NCT00950963)
- Testing
- Phone Counseling, Standard Clinical Care
- Where
- United States
- Volunteers
- 762 people
- Sponsor
- Denver Health and Hospital Authority
Rheumatoid Arthritis
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
Primary Objective: To demonstrate that sarilumab (SAR153191/REGN88) on top of methotrexate (MTX) was superior in efficacy to placebo for the relief of signs and symptoms of rheumatoid arthritis (RA), in participants with active…
- Trial name
- NCT01217814
- Testing
- Sarilumab, Golimumab, methotrexate (MTX)
- Where
- 14 sites in United States, Colombia and 4 more
- Volunteers
- 16 people
- Sponsor
- Sanofi